Refine your search

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

410 Study Matches

Effect of radiofrequency ablation and posterior fusion on the function of the lumbar multifidus

The objective of this study is to evaluate changes in function of the multifidus muscle in patients who have undergone radiofrequency ablation (RFA) or posterior lumbar fusion procedures (PLIF). Male and female patients in the age range of 18 to 80 years old who have recently (less than a year) undergone PLIF or RFA in the lumbar spine are being recruited. Compensation of $50 is available.
Daniel Cortes at researchsubjects@mne.psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
posterior fusion surgery lumbar spine
radiofrequency ablation lumbar spine
Exclusion Criteria:
younger than 18
older than 80
pregnant women
other neuromuscular conditions
Muscle & Bone
  Email this study information to me
  Contact the study team
  Show all 2 locations

Study Locations

Hide all locations
Location
Hershey, PA
State College, PA

A Single Arm Phase II Study of Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium (BTCRC-BRE15-016) (16-053)

Primary Objective The primary objective of the Phase II study is to estimate the activity of the combination of palbociclib and tamoxifen in first line therapy for women with HR(+)/HER2(-) advanced breast cancer who have not received prior systemic anti-cancer therapies for their advanced/metastatic disease, assessed by response rates (complete or partial response) (RR) based on RECIST 1.1 or MDA criteria (for patients with bone only disease). Secondary Objectives - Characterize safety and tolerability of palbociclib and tamoxifen in first line therapy for women with HR(+)/HER2(-) advanced breast cancer who have not received prior systemic anti-cancer therapies for their advanced/metastatic disease. - Evaluate progression-free survival (PFS) per local assessment and RECIST 1.1 or MDA criteria in subjects with HR(+)/HER2(-) advanced breast cancer who have not received prior systemic anti-cancer therapies for their advanced/metastatic disease treated with palbociclib in combination with tamoxifen. - Evaluate clinical benefit rate RR (complete, partial response, or stable disease, lasting 24 weeks or longer) based on RECIST 1.1 or MDA criteria in subjects with HR(+)/HER2(-) advanced breast cancer who have not received prior systemic anti-cancer therapies for their advanced/metastatic disease treated with palbociclib in combination with tamoxifen. - Measure overall survival (OS) at 2 years in subjects with HR(+)/HER2(-) advanced breast cancer who have not received prior systemic anti-cancer therapies for their advanced/metastatic disease treated with palbociclib in combination with tamoxifen.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02668666
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Locally advanced, locoregionally recurrent, or metastatic disease, not amenable to curative therapy
Histologically and/or cytologically confirmed diagnosis of ER positive and/or PR positive (ER>1%, PR>1%), Her2 negative breast cancer
No prior systemic anti-cancer therapy for advanced HR+ positive disease
Metastatic disease evaluable on imaging studies.
Adequate blood, liver and kidney function
Exclusion Criteria:
Prior treatment with any CDK 4/6 inhibitor
Confirmed diagnosis of HER2 positive disease
Known uncontrolled or symptomatic CNS metastases.
Prior (neo)adjuvant treatment with tamoxifen within the 12 months before study entry.
Prior history of blood clots, pulmonary embolism or deep vein thrombosis.
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Randomized Controlled Trial of Smartphone Treatment for Anxious and Depressed Individuals

This study aims to examine the efficacy and effectiveness of a brief 14-day smartphone-delivered treatment on depressed and anxious individuals, particularly university undergraduates. We hope that the brief treatment will help to alleviate psychological distress.
Hani Zainal at nvz5057@psu.edu or 907-767-7088
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Owns a smartphone compatible with the treatment app (iPhone or all Android phones except for Life’s Good brand).
Aged 18 years and above.
Motivated to seek treatment for anxiety and depression.
Fluent in the English language in terms of speaking, listening, reading, and writing.
Exclusion Criteria:
Unable to consent.
Has a mental health condition that warrants in-person professional mental health treatment.
Unable to commit to the study duration for whatever reasons.
Unable to speak, read, listen, and write English fluently.
Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

PA CURE Phase 1: Biomarkers of Traumatic Brain Injury (TBI)

The study seeks to identify the characteristics of brain function after traumatic brain injury (TBI). The data obtained through this study aims to help physicians better understand the characteristics of specific products released into the blood and cerebrospinal fluid (CSF) following a TBI, called biomarkers. In addition, we will store blood and CSF samples for later testing as new information becomes available. The long-term goal of this study is to provide physicians with the tools they need to diagnose brain injuries. This information may help doctors judge how severe a head injury is, if treatment needs to be adjusted, and it may help predict how well a patient recovers from the injury.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Traumatic brain injury within the preceding 24 hours requiring admission to the ICU
Current age 18-60 years
Head CT with acute intracranial pathology
Ability to undergo MR and PET imaging
Exclusion Criteria:
Penetrating TBI due to gunshot wound, shrapnel, or other metallic substance that would preclude patient from undergoing MR imaging
Pre-existing neurologic or neurodegenerative disorder or history of psychiatric conditions, such as major depressive disorder or psychosis
Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with neuropsychological testing
Contra-indication to MR imaging, such as ferrous metal, pacemakers, body weight above 125 kg, or concerns about claustrophobia
Non-native English speakers (translations are not available/validated for most neuropsychological test measures).
Neurology
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

iVR for the Geosciences

Fieldwork is a core activity in the geosciences. Immersive technologies, such as virtual reality (VR), allow for embodied experiences while not physically present at a field site or create experiences not possible in physical reality. Immersive VR (short: iVR) refers to systems using head-mounted displays to deliver 360-degree experiences. It can deliver remote and large-scale geological entities to the laboratory, allowing geoscientists to apply real-world skills and methods to explore and interact with 3D geological models. We describe a project in which we developed an iVR workbench and experience for Iceland’s Thrihnukar volcano combining satellite imagery with terrain elevation data to create a basic reconstruction of the real world, using terrain elevation terrestrial LiDAR data to provide a point cloud model of the entire magmatic-volcanic system and intensity values for the identification of rock types, and Structure from Motion (SfM) mapping to construct a photorealistic point cloud of the volcano. To reproduce fieldwork activities, this project digs deeply into the scientific workflow of geosciences research, evaluates the priorities of the major phases of geosciences fieldwork, and develops a prototype immersive workbench for direct manipulation, information retrieval, geometric measurement, and the integration of multimedia resources. This workbench offers analytic functions currently not available in the field and is expected to help making fieldwork experiences accessible, shareable, and available any time. Future developments will also allow for collaborating remotely as well as designing repositories for comparative studies.
Jiayan Zhao at juz64@psu.edu or 814-321-6982
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Graduate Students
Major in disciplines related to Earth Sciences (e.g., Geosciences, Geography, and Environmental Science)
Exclusion Criteria:
Younger than 18 years old
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Interactions between the olfactory, auditory, visual, and trigeminal systems

The purpose of this study is to use fMRI to identify and characterize the olfactory, auditory, visual and trigeminal-related brain networks. This research will then be use to enhance human health by laying the foundation to develop sensitive biomarkers to identify people who are at risk of developing brain disorders such as Alzheimer’s disease and Parkinson’s disease, where olfactory deficits are known preclinical symptoms.
Michelle Douthitt at mld43@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Healthy subjects (non-synesthetic) with normal olfactory, visual, and hearing abilities
Healthy subjects (synesthetic) with normal olfactory, visual, and hearing abilities
Clear sinuses
Exclusion Criteria:
Non-English speaking
Pregnant or lactating
Presence of a pacemaker, aneurysm clips or any metal in the body
A history of welding, grinding, and or claustrophobia
Neurological disease (stroke, tumor, Parkinson's) or Psychiatric disorder (bipolar, schizophrenia, etc)
Neurology
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Neurocomputational Mechanisms of Affiliation and Personality (NeuroMAP)

This study seeks to learn how brain changes in young adults may be related to the development of interpersonal and emotional functioning, as well as risky behavior. This research is being done to find out the differences in the ways that emerging adults regulate their emotions and behavior and how this is reflected in computer-based tasks and fMRI.
Begonia Herbert-Ramirez at bbh5255@psu.edu or 814-863-7624
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18-25 years old
Weigh less than 250 lbs.
Fluent English speaker
Exclusion Criteria:
Metal in body
Neurological disorder (autism, developmental disorder)
Current pregnancy
Less than 20/40 far acuity (corrected or uncorrected)
Men's Health, Mental & Behavioral Health, Women's Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Site for A Phase III Randomized Trial Comparing Adjuvant MK3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

The purpose of this Phase III study is to compare Overall Survival (OS) and Recurrence Free Survival (RFS) across the two arms: MK3475 (Pembrolizumab) to Standard of Care Observation. Patients will undergo standard clinical procedures including physical, labs, vitals, ecg's, and imaging.
Irina Geier at iug29@psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03712605
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patients must have an ECOG performance Status: 0, 1, or 2
Patient must have a histological confirmation of diagnosis of Merkel cell carcinoma (MCC), pathologic stages (AJCC version 8) I-IIIb.
completely resected by surgery within 8 weeks before enrollment.
All patients must have disease-free status documented by a complete physical examination and conventional imaging studies within 4 weeks prior to randomization.
Patients must not be on active immunosuppression, have a history of life threating virus, have had other cancer diagnoses in the last two years
Exclusion Criteria:
Women who are pregnant
present metastases
previous systemic therapy or radiation therapy for Merkel cell carcinoma.
inoperable disease who have received radiation are not eligible.
history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Effects of Individualist and Collectivist Culture on Emotional Empathy in Counselor Trainees

This research is an attempt to understand the components of empathy and the cultural factors that shape its development. I am seeking about 200 Master's-level counseling students in the U.S. to complete the online survey. The survey takes about 15 minutes to complete, and participants will have chances to win Amazon gift cards and to learn the study results.
Qu Chen at qbc5002@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Currently enrolled in a counseling program at the Master's level
over 18-year-old
Exclusion Criteria:
Not a Master's-level counseling student
under 18-year-old
Education, Mental & Behavioral Health
  Email this study information to me
  Contact the study team

A Phase 2b, Single-Arm, Multicenter Trial to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk of Recurrence

This study is for patients with bladder cancer (low-grade non-muscle-invasive) who are at an intermediate risk of recurrence. The purpose of this study is to evaluate the effectiveness and safety of an experimental gel which will serve as a reservoir for a more prolonged release of a type of chemotherapy locally in the bladder.
Kathleen Lehman at klehman3@pennstatehealth.psu.edu or 717-531-5930
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03558503
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Newly diagnosed or historic LG NMIBC (Ta) histologically confirmed by cold cup biopsy at screening or within 6 weeks of screening
At intermediate risk for progression, defined as having 1 or 2 of the following: a. presence of multiple tumors, b. solitary tumor >3 cm c. recurrence (≥ 1 occurrence of LG NMIBC within 1 year of the current diagnosis).
Negative voiding cytology for HG disease at or within 6 weeks of enrollment.
Exclusion Criteria:
History of CIS on preliminary cystoscopy within 5 years of enrollment.
Received BCG treatment for UC within previous 2 years.
History of HG papillary UC in the past [2] years
History of pelvic radiotherapy.
Past or current muscle invasive (i.e., T2, T3, T4) or metastatic UC or concurrent upper tract urothelial carcinoma (UTUC).
Kidney & Urinary System, Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Examining executive functioning deficits, affective deficits, and social functioning to better understand disruptive behaviors and callous-unemotional traits

This research seeks to better understand functioning in children who differ in symptoms of Attention-Deficit Hyperactivity Disorder (ADHD), conduct problems (CP), and callous-unemotional (CU) traits, ages 6 - 13. Specifically, this research is being done to find out how these different types of behaviors impact cognitive skills (like attention, impulsivity, working memory, emotion identification) and social functioning to help inform future treatment with these children.
All
Younger than 18 years old
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Children ages 6 to 13 years old
Estimated IQ of 80 or above
Willing and able to discontinue psychoactive medication treatment for the experiemental session, if relevant
Caregiver and child must be fluent in written and spoken English
Exclusion Criteria:
Current or past diagnosis of intellectual disability, any psychotic disorder or autism spectrum disorder, or schizophrenia or rleated disorders
Psychiatric symptoms requiring urgent treatment, such as mania or suicidal ideation/homicidal ideation
Unable to be tested off medication
Physical disabilities that are incompatible with completing laboratory tasks such as hearing or speech impairments, or visual impairments that cannot be corrected with visual aids
Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Measuring Neuroadaptations in Response to Very Low Nicotine Content Cigarettes

For this study, 75 smokers will be randomly assigned to smoke research cigarettes with a very low or normal nicotine content. Participants will complete functional magnetic resonance imaging (MRI) scans at 3 in-person study visits to help us better understand how reducing nicotine intake affects decision making and reward processing.
Brianna Hoglen at abl@pennstatehealth.psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
NCT03612960
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Smoke greater than or equal to 5 cigarettes per day
21-60 years old
>1 year daily smoking
Live local for next 3 months
No plans to quit smoking in next 6 mos.
Exclusion Criteria:
Regular use of non-cigarette tobacco products
MRI safety contraindications
Unstable or significant medical conditions
smell dysfunction
colorblindness
Addiction & Substance Abuse
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Evaluation of the Immune Response and Antigenic Signature of Patients with Babesia Infection in Pennsylvania with the Aim of Developing a Rapid Diagnostic Test

We are evaluating patients who have been infected with Babesia. Babesia is a blood parasite that is acquired from ticks. The number of cases seen in Pennsylvania every year has been increasing. We intend to evaluate the blood of patients acutely infected with Babesiosis and compare it to the blood of healthy individuals. We hope to identify proteins in the blood of acutely infected patients that are specific for Babesia that could then be used to create a rapid diagnostic test.
David Ingram at dingram@pennstatehealth.psu.edu or 717-531-8881
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Healthy
18 years or older
Exclusion Criteria:
Active Cancer
History of having your spleen removed
History of liver or kidney disease
HIV
Diabetes
Infectious Diseases & Immune System
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Everyday Experiences Study

This study examines how different types of emotions and events that people experience as they go about their everyday life may relate to their health. Participants will be asked questions related to their emotions and health six times a day for a week. Additionally, they will be asked a morning and evening survey about expectations for the day, sleep, and physical health.
Dusti Jones at dmj5352@psu.edu or 814-867-1682
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Aged 25-65
Own a smartphone
Fluent in English
Exclusion Criteria:
Diagnosis of depression or anxiety disorder
Retired
Undergraduate student
Prevention, Sleep Management, Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

A Phase 3, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis

This study is for patients with IPF (Idiopathic Pulmonary Fibrosis) to see how well a new medication works with current standard treatment on lung function and IPF disease in general.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03711162
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 40 or greater
Diagnosis of Idiiopathic Pulmonary Fibrosis (IPF) within the past 5 years
Exclusion Criteria:
HIV or hepatitis B or C diagnosis
History of malignancy within the past 5 years
Acute IPF reoccurrence in the past 6 months
Lower respiratory tract infection in the past 4 weeks requiring antibiotics
History of lung volume reduction surgery or lung transplant
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Modulating Role of Vitamin D in Oxidative Stress-Induced Vascular Dysfunction

Cardiovascular disease (CVD) is a leading cause of sickness and death. Studies have shown higher risk of CVD in African Americans (AA). The reasons for this higher risk are not well understood. Vitamin D may play a role in blood vessel health and reduce risk of CVD. Darker skin absorbs light from the sun, and reduces the amount of vitamin D made by the body. We think that lower vitamin D in AA may lead to reduced blood vessel health and increased risk of CVD. This study will look at differences in nitric oxide that helps blood vessels relax. We will also look at “oxidant stress,” which can reduce nitric oxide. In this study, we will examine the function of blood vessels in the skin. The blood vessels in the skin are a model for blood vessels in other organs in the body. We will also look at the function of other, larger blood vessels in the body. This research is being done to find out why blood vessel function is reduced in young AA adults who are healthy. The research is also being done to find out if vitamin D will improve blood vessel function. Approximately 24 people will take part in this study at the Noll Lab.
Tony Wolf at saw85@psu.edu or 814-863-8556
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18
•35 years old
Normal blood pressure
Normal cholesterol
Normal blood glucose
African or European American descent
Exclusion Criteria:
Smoking
Use of illegal/recreational drugs
Known skin allergies
Diagnosed or suspected metabolic or cardiovascular disease
Current pregnancy or breastfeeding
Heart & Vascular
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Abdominal Binders to Compensate for Neurogenic Restrictive Lung Disease in Adults with Spinal Cord Injury

This research is being done to find out if the use of abdominal binders improves lung function, phonation (vocal sounds), and singing in individuals with SCI.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Cervical or Thoracic Spinal Cord Injury
Ages 18-75
ASIA A or B
Exclusion Criteria:
Ventilator dependent
Cystic Fibrosis
COPD
Lung Disease & Asthma, Neurology
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Phase II Trial of Palbociclib with Fulvestrant in Individuals with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer who have Progressed on Treatment with Palbociclib and an Aromatase Inhibitor

In this phase II trial, we will determine the progression-free survival (PFS) of the cyclin dependent kinase 4/6 inhibitor (CDK4/6i) palbociclib with fulvestrant in women and men with estrogen or progesterone receptor (ER/PR) positive, HER2-negative metastatic breast cancer (MBC) who progressed on treatment with palbociclib and an aromatase inhibitor (AI). We will also determine the prevalence rate of estrogen eceptor α (ESR1) and phosphatidylinositol-3-kinase (PI3K) mutations in the study population.
Lea May at lmay1@psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02738866
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Men and women, 18 years of age or older
Histologically or cytologically confirmed adenocarcinoma of the breast with evidence of metastatic disease (stage IV) or locally advanced disease,
ER-positive and/or PR-positive tumor (≥1% positive stained cells) • HER2-negative tumor
Progressed on and following at least 6 months of combined treatment with palbociclib and AI therapy for advanced/metastatic breast cancer, and be able and willing to receive additional palbociclib treatment
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Exclusion Criteria:
Women who are pregnant or breast-feeding
Concurrent use of any of the following medications during study participation: • Inhibitors or inducers of CYP3A4 that may affect serum concentrations of palbociclib
Major surgery, chemotherapy, radiotherapy, or other anti-cancer therapy within 2 weeks before registration.
Any other malignancy within 3 years prior to registration, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.
Prior hematopoietic stem cell or bone marrow transplantation.
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Computer-Human Team Problem-Solving

This project examines team problem solving. Participants will work individually or in small groups to solve problems alone or in collaboration with a computer (AI) program, presented either as puzzles or in case studies. Participants may be occasionally asked to self-report concerning the problem, their own or their group's progress, and/or other aspects of their solving.
Christopher McComb at mccomb@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be an engineering student
Must be at least 18 years of age
Exclusion Criteria:
Must be an engineering student
Must be at least 18 years of age
Education
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Diet and stress responses in low-income rural adults under the dynamics of food insecurity

The study is recruiting adults in rural Central Pennsylvania to understand how their food environment in fall and winter predicts diet, stress, mood, and health in everyday life. Participants will use a provided survey phone to answer the survey questions and will use a provided chest belt to measure heart rate for 5 mins every day in the morning during the study period. There will be up to 2 training session in State College, PA or a community center in Woodland, PA. Data collection will take place at participant's home. Study compensation and travel compensation will be provided.
Muzi Na at muzi.na@psu.edu or 814-865-2919
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adults between 20-50 years
In general good health
If female, prior to menopause
Household income <= 185% of the poverty level
Exclusion Criteria:
Has any physical, mental or emotional disabilities
Is pregnant
Non-English speaking
Food & Nutrition, Heart & Vascular, Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  Show all 2 locations

Study Locations

Hide all locations
Location
DuBois, PA
State College, PA

Investigating Design Aspects of Immersive Virtual Field Trips and Site Experiences

This study investigates the effects and effectiveness of different options for designing immersive virtual reality tours of real-world places. Participants will wear a Virtual Reality headset and watch several short tours featuring different environments (museum, forest, harbor, Mayan site). After each tour, participants will be asked for their opinion on certain design aspects of the tour app.
Mahda Bagher at mmm6749@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
at least 18 years old
English speaking
able to wear a VR headset + sit and turn in a swivel chair while watching the short VR tours
able to listen to the tour's audio commentary
Exclusion Criteria:
younger than 18
non-English speaking
Education
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

A randomized, double-blind, placebo-controlled, phase 2 trial assessing the efficacy, safety and dose-response of quinagolide extended-release vaginal rings administered sequentially for 8 menstrual cycles in women with moderate to severe endometriosis-related pain

To evaluate the efficacy of three doses of quinagolide administered as an extended-release vaginal ring compared to placebo on reduction of moderate to severe endometriosis-related pain
Barbara Scheetz at bscheetz@pennstatehealth.psu.edu or 717-531-4483
Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03692403
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of endometriosis
pre-menopausal females age 18 and over
history of regular menstrual cycles
moderate to severe endometriosis related pain
Exclusion Criteria:
pregnant or breastfeeding
chronic pelvic or abdominal, or lower back pain not related to endometriosis
history of recurrent bacterial or fungal vaginal infection
current use of hormonal medication will require a washout period
Women's Health
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Comparing barriers to cancer screening across PSCI catchment area county types: Implications for a self-sampling intervention – Patient surveys

In this study, we will conduct surveys with women, ages 45-65 years, who are patients in the Penn State Cancer Institute (PSCI) catchment area which includes rural/urban and segregated/not segregated counties in Pennsylvania to learn more about their barriers to cancer screening.
Female
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Female residing within the PSCI catchment area
45-65 years of age
Able to speak, read, and communicate well in English
Exclusion Criteria:
Children
Cognitively impaired
Cancer, Women's Health
  Email this study information to me
  Contact the study team

National Study of College Students Formerly in Foster Care

This study will examine the educational experiences and outcomes of youth who have experience with the foster care system in the United States. We are interested in understanding the protective and risk factors that influence college success for youth in foster care. This study involves a three round interview process. Each interview will be approximately 60-90 minutes.
Bridget Parler at bap62@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Identify as having experience being in the foster care system in the United States
Must be currently enrolled in a college or university
Must be at least 18 years old
Exclusion Criteria:
Does not identify as previously been in foster care in the United States
Under 18 years of age
Education
  Email this study information to me
  Contact the study team

One Penn State : Connecting a Learning Community of Geographically Diverse Students

The community of remote learners is on the rise. With the trends of application and skill based knowledge, more and more people are migrating to the learn while you work paradigm. People value flexibility and comfort increasingly. Penn State is one of the few Universities propagating the cause of spreading knowledge via all modalities. The 33,302 students spread across its 19 commonwealth campuses are further a testimony to the prevalent trends. It is important that all these students receive an integrated and cohesive student experience. This also covers the need for the students to feel a sense of social belongingness. The work will focus on bringing together the Penn State community to achieve the true essence of it’s chant WeAre!
Sanjana Gautam at sqg5699@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be 18 years of age or older
Must be a student of Penn State
Exclusion Criteria:
Most not be younger than 18 years of age
Education
  Email this study information to me
  Contact the study team

A Phase 3 multicenter, randomized, double-blind, placebo-controlled, clinical study to assess the efficacy and safety of linzagolix in subjects with moderate to severe endometriosis-associated pain.

The purpose of this study is to look at the safety and efficacy of different doses of linzagolix alone and together with so-called ‘add-back therapy’ (hormones) compared to placebo (an inactive sugar pill) in women with moderate to severe pain associated with endometriosis. Endometriosis is when tissue that normally grows inside the uterus grows outside the uterus. It is one of the most common gynecological diseases. The condition is mainly found in women in their reproductive years and disappears spontaneously after menopause. Symptoms can include painful periods, chronic pelvic pain, pain with bowel movement, pain during intercourse and urination problems. Linzagolix is an experimental drug which is not approved for the treatment of moderate to severe pain associated with endometriosis. Linzagolix has been shown to significantly reduce pain associated with endometriosis in women with endometriosis at once daily doses between 50 and 200 mg with a good safety and tolerability profile. About 450 women will take part in this study at a number of different locations in the US and Canada. This study will have up to 16 study visits over a period of approximately 15 months.
Heidi Watts at hwatts@pennstatehealth.psu.edu or 717-531-6272
Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03986944
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Women aged 18
•49 years old
Has had surgery to diagnose endometriosis up to 10 years before screening
Has moderate to severe endometriosis associated pain
Must agree to take only those pain medications permitted by the study during participation
Exclusion Criteria:
Pregnant, planning to become pregnant or breastfeeding. If recently pregnant, must be at least 6 months post-partum or 3 months post-abortion/miscarriage
Surgical history of hysterectomy, Essure device, endometrial ablation resulting in amenorrhea, both ovaries removed, bowel resection or gastric bypass
Has had surgery for endometriosis in the last 6 months or planning surgery for endometriosis during study participation
Chronic narcotic use, alcohol or illicit drug abuse or prescribed medical marijuana
Pain Management, Women's Health
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site for A Comparative Effectiveness Randomized Controlled Trial of Mindfulness Meditation versus Cognitive Behavioral Therapy for Opioi-Treated Chronic Low Back Pain

This study will use mindfulness meditation (MM) or cognitive behavioral therapy (CBT) on patients with chronic low back pain to help improve their health outcomes and reduce opioid dependence. Subjects will be randomized to the MM or CBT group and asked to complete at home or group activities while also completing surveys.
Amanda Taylor Gehman at ataylor6@pennstatehealth.psu.edu or 717-531-1283
All
18 year(s) or older
This study is also accepting healthy volunteers
NCT03115359
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adult 21+
Diagnosis of chronic low back pain
Treatment with pain medication for three months or more
Capable of providing informed consent
Exclusion Criteria:
Prior Mindfulness Meditation or Cognitive Behavioral Therapy training
Pregnant women
Diagnosed with borderline personality, delusional or bipolar disorders
Pain Management
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A comparison of VR and MR in Human-ECA interaction

We are conducting this study to investigate whether different platforms of immersive technology influence the experiences of users when interacting with an embodied conversational agent. We are particularly interested in studying the effects of platform on users’ feelings of presence and social presence when comparing virtual and mixed reality environments.
Pejman Sajjadi at sfs5919@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Corrected to near corrected vision
English speaking
Exclusion Criteria:
Hearing impairment
Education
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

A Phase I/II, Multicenter, Open Label, Multi Arm Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Preliminary Activity Of Idasanutlin In Combination With Either Chemotherapy Or Venetoclax In The Treatment Of Pediatric And Young Adult Patients With Relapsed/Refractory Acute Leukemias Or Solid Tumors

A study of the safety of idasanutlin for children with solid tumors and leukemias that returned or did not respond to previous treatment.
Suzanne Treadway at streadway@pennstatehealth.psu.edu or 717-531-3097
All
All
This study is NOT accepting healthy volunteers
NCT04029688
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
1-30 year of age
Have a solid tumors or leukemia that returned or did not respond to previous treatment
Exclusion Criteria:
Have a primary CNS tumor
Have uncontrolled infection
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Defining the cellular and molecular signatures that are associated with the clinical heterogeneity of hidradenitis suppurativa

Patients with the clinical diagnosis of mild, moderate to severe Hidradenditis Suppurativa or normal healthy volunteers ages 18 and older to participate in a 1 time study visit. There is no treatment provided but we may gain information for the treatment of HS.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-1513
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years and older
Hidradentitis Suppurativa diagnosis for 3 months
Normal skin participants
Exclusion Criteria:
Patients who are Pregnant
Normal skin participants do not have an autoimmune disease
Participants who do not want to have any of the lesion sampling performed
Skin Conditions
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA